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Abstract
The endocannabinoid system has been implicated in several neurobiological processes, including
neurodegeneration, neuroprotection and neuronal plasticity. The CB1 cannabinoid receptors are abundantly
expressed in the basal ganglia, the circuitry that is mostly affected in Parkinson’s Disease (PD). Some studies show
variation of CB1 expression in basal ganglia in different animal models of PD, however the results are quite
controversial, due to the differences in the procedures employed to induce the parkinsonism and the periods
analyzed after the lesion. The present study evaluated the CB1 expression in four basal ganglia structures, namely
striatum, external globus pallidus (EGP), internal globus pallidus (IGP) and substantia nigra pars reticulata (SNpr) of
rats 1, 5, 10, 20, and 60 days after unilateral intrastriatal 6-hydroxydopamine injections, that causes retrograde
dopaminergic degeneration. We also investigated tyrosine hydroxylase (TH), parvalbumin, calbindin and glutamic
acid decarboxylase (GAD) expression to verify the status of dopaminergic and GABAergic systems. We observed a
structure-specific modulation of CB1 expression at different periods after lesions. In general, there were no changes
in the striatum, decreased CB1 in IGP and SNpr and increased CB1 in EGP, but this increase was not sustained over
time. No changes in GAD and parvalbumin expression were observed in basal ganglia, whereas TH levels were
decreased and the calbindin increased in striatum in short periods after lesion. We believe that the structure-specific
variation of CB1 in basal ganglia in the 6-hydroxydopamine PD model could be related to a compensatory process
involving the GABAergic transmission, which is impaired due to the lack of dopamine. Our data, therefore, suggest
that the changes of CB1 and calbindin expression may represent a plasticity process in this PD model.
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Introduction
The cannabinoid compounds are lipophilic molecules which
exert their effects by binding to specific membrane receptors
[1]. Two types of cannabinoid receptors, both coupled to G
proteins, have been identified (CB1 and CB2). These two
receptors control peripheral and central functions [2,3]. In
addition, more recently it has been shown that cannabinoids
can also bind to other types of receptors, such as the transient
receptor potential vanilloid-1 (TRPV1) [4] and peroxisome
proliferator-activated receptor (PPAR) family of nuclear
receptors [5]. Endocannabinoids are usually released from
target neurons and act as retrograde messengers that regulate
synaptic transmission. The activation of presynaptic CB1
results in inhibition of the release of some neurotransmitters,
such as glutamate and γ-aminobutyric acid (GABA) [6,7].
High amounts of CB1 are found in the basal ganglia
[substantia nigra (SN), globus pallidus (GP), entopeduncular
nucleus and lateral striatum], cerebellum, and hippocampus
[1,3,8]. In the striatum, the highest expression of CB1 occurs in
its dorsolateral portion [9] mainly in the terminals of cortical
projection neurons and in GABAergic interneurons. In SN, CB1
receptors are located in the terminals of spiny striatal neurons
in the pars reticulata (SNpr). Dopaminergic projections from SN
innervate the striatal neurons that express CB1 and the
dopamine receptors D1 and D2. The D2 and CB1 receptors
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share a group of G proteins, indicating a convergence of their
transduction mechanisms. On the other hand, the activation of
D1 receptors, mediated by adenylyl cyclase, can be completely
blocked by CB1 stimulation. In the medial portion of globus
pallidus (also known as internal globus pallidus – IGP) and in
the SNpr it is well established that the activation of CB1
reduces the release of both GABA and glutamate from
terminals originating in the striatum and subthalamic nucleus,
respectively [10–14]. In addition to the high expression of CB1
in the basal ganglia, endocannabinoid ligands and their
synthesizing and degrading enzymes are also particularly
abundant in those structures [15].
Parkinson’s disease (PD) is a neurodegenerative disorder
associated with loss of 50 to 70% of dopaminergic neurons in
the SN pars compacta (SNpc), which has been extensively
investigated in regard to its behavioral and molecular aspects,
both in animal models and humans [16,17]. The loss of
dopamine in the projection area of the SNpc neurons leads to a
functional change in the complex circuitry of the basal ganglia
[18], which results in an excessive inhibition of motor systems
[19]. The high density of CB1 receptors and endocannabinoids
found in the basal ganglia has been a much explored research
field that seeks to understand the relation between PD and the
cannabinoid system, which has led to prospects for
cannabinoid therapies. Indeed, several studies have shown the
participation of cannabinoid system in different kinds of
neurodegenerative diseases and suggested its neuroprotective
properties [20–23]. A recent study with humans, for instance,
showed a marked decrease of CB1 in the SN of PD patients,
concomitant with a slight increase in dopaminergic projection
areas [24]. Delta9-tetrahydrocannabinol (delta9-THC) is able to
reverse the decreased dopaminergic transmission in the basal
ganglia of a mice model of PD [25].
Studies employing different animal models of PD, such as 6-
hydroxydopamine (6-OHDA) injections in basal ganglia or
intracerebroventricular in rats [26–29], intraperitoneal injections
of heroin contaminant 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in marmosets and mice [30], and
specific park genes deleted- mice [31], for example, have also
reported changes of CB1 expression in the basal ganglia.
However, the data are heterogeneous and often conflicting.
Those heterogeneous results seem to depend on the
procedures employed to induce parkinsonism and the periods
analyzed after the lesion [32].
Temporal variation of CB1 expression during PD progression
is poorly understood. Furthermore, most studies are devoted to
evaluate CB1 variation focusing on the striatum and SN, and
giving minor attention to the other basal ganglia structures,
such as external and internal globus pallidus (EGP and IGP,
respectively – [33]). Therefore, the aim of this study was to
analyze the time course of CB1 receptor expression by
immunoshistochemistry in four structures of basal ganglia,
namely striatum, EGP, IGP, and SN, in the PD model of
unilateral intraestriatal injections of 6-OHDA in rats. The 6-
OHDA injection directly into the striatum causes retrograde
dopaminergic degeneration [16]. We also evaluated the
expression of tyrosine hydroxylase (TH), glutamic acid
decarboxylase (GAD), parvalbumin, and calbindin, by
immunoshistochemistry and/or immunoblotting, in an attempt to
establish relationships between the cannabinoid system and
the dopaminergic and GABAergic systems.
Materials and Methods
Animals
Seventy-days-old male Wistar rats weighting 230-280g at the
beginning of the experiments, provided by the central animal
house of the Institute of Biomedical Sciences, University of São
Paulo, were used in this study. The animals were housed in
groups of 3–4 animals per cage, maintained at 23 °C ± 2, in a
12 h light/12 h dark cycle (lights on at 06:00 h), with free
access to food and water. The experiments were carried out in
accordance with the guidelines of the Brazilian College for
Animal Experimentation (COBEA) and were approved by The
Ethics Committee for Animal Research of the Institute of
Biomedical Sciences, University of São Paulo (Protocol n°
27/68/2), which are in accordance with the procedures of
national and international care of animals used in scientific
research.
Independent groups of rats were used to investigate the time
course effects of 6-OHDA striatal injection on protein levels by
immunohistochemical and immunoblotting analysis.
Surgical procedure and unilateral injection of 6-OHDA
Rats were anesthetized with 2,2,2-tribromoethanol (1 mL/100
g -250 mg/kg i.p. - Sigma®) and placed in a stereotaxic frame
(David Kopf Instruments). After craniotomy, two 0.5 µl
injections containing 6 µg of 6-OHDA in saline and 0.3%
ascorbic acid (totalizing a final dose of 12 µg) were made in the
right striatum by way of glass micropipettes coupled to a
pressure system, in the following coordinates: (1) AP: bregma,
ML: -2.7, and DV: -4.5mm, (2) AP: -0.5, ML: -3.4, and DV: 4
mm [33]. Once the infusion was finished, the micropipette was
maintained still in the infused region for approximately one
minute to avoid solution reflux, and then it was slowly removed
from the brain. The incision was then sutured and treated with
Fibrase® (Pfizer) in order to improve healing. The brains of PD-
induced rats were then analyzed after 1, 5, 10, 20, and 60 days
of the 6-OHDA injections (days post-lesion, DPL). The basal
ganglia structures of the lesioned side (right) were always
compared to their corresponding in the intact side (left).
Transcardiac perfusion and Immunohistochemistry
PD-induced rats were deeply anesthetized with ketamine (5
mg/100 g of body weight, im) and xylazine (1 mg/100 g of body
weight, im), and perfused through the left ventricle with
phosphate-buffered saline and 4% paraformaldehyde in 0.1 M
phosphate buffer (PB, pH 7.4). The brains were dissected out
and after 4-6 hours post-fixation in paraformaldehyde solution
they were transferred to a 30% sucrose PB solution to ensure
cryoprotection. Coronal sections (30 µm) were then obtained
on a sliding microtome and collected in PB.
Sections containing substantia nigra (SN), striatum and
globus pallidus (GP) regions were incubated with rabbit
polyclonal antiserum anti-CB1 (Cayman, Ann Arbor, MI, USA,
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1:1,000), a mouse monoclonal anti-tyrosine hydroxylase
antibody (TH; Chemicon, Temecula, CA, USA, 1:1,000) as an
indicator of dopaminergic neurons in basal ganglia; a mouse
monoclonal anti-parvalbumin antibody (Sigma®; 1: 1,000), and
a mouse monoclonal anti-calbindin antibody (Sigma®; 1:
1,000), as indicators of GABAergic neurons in striatum, in PB
containing 0.3% Triton X-100 plus 5% of normal goat or donkey
sera. Parvalbumin is known to be present in GABAergic
neurons in the basal ganglia [34,35]. Immunolabeling with
peroxidase methods was conducted as previously described
[36]. Controls for CB1 staining included: (1) omission of the
primary antibody and (2) preadsorption of the primary antibody
overnight with a 10-fold excess of the corresponding control
peptide for CB1 (Cayman).
Digital images were acquired using a Nikon E1000
microscope (Melville, NY, USA) and Nikon DMX1200 digital
camera (Nikon Imaging Software ACT-U). Images from
striatum were captured between bregmas 1.80 and -0.36; from
EGP between bregmas -0.24 and -3.12; from IGP between
bregmas -1.92 and -2.76; and from SNpc and SNpr between
bregmas -4.56 to -6.60 (4-8 sections/brain/structure; n= 4-5 per
DPL) [33]. All structures were analyzed by obtaining images at
certain intervals between each other in order to represent its
entire length, thus ensuring an overview of each structure.
Representative images were mounted with Adobe Photoshop
(Adobe Systems Inc., Mountain View, CA, USA).
The TH expression was quantified in the striatum (6
sections) and SNpc (6-8 sections) as an indicator of the lesion
extension. Parvalbumin and calbindin were quantified in the
striatum (6 sections), parvalbumin in dorsolateral striatum and
calbindin in ventromedial striatum. CB1 receptor expression
was quantified in the striatum (6 sections), EGP (4 sections),
IGP (4 sections), and SNpr (6 sections), all carried out with
ImageJ (NIH/USA). For TH in SNpc, CB1 in EGP, IGP and
SNpr, we measured the integrated density of immunolabeling
and of the background (nonlabeled areas) from each slice. The
background integrated density was deduced from the
integrated density quantification of the labeled areas, to obtain
a labeling index reflecting the signal-to-noise ratio. For CB1
immunostaining in the striatum the average of the integrated
density of three areas of 2500 µm2 was conducted. For
parvalbumin and calbindin in the striatum, positive cells were
directly counted. After the quantification blind researchers to
the experimental conditions (side and days after lesion)
reviewed the data. The resulting indexes were always
normalized to the controls.
Immunoblotting
At the same time points described above, the rats (n=6-8 per
group) were sacriﬁced by cervical dislocation, and the SN
(bregma -4.56 to -6.60 below colliculus approximately), and
striatum (bregma +2.28 to -1.32, approximately) [33] were
rapidly collected. The immunoblotting assay was conducted as
previously described [36]. In short, samples containing 30–40
µg protein were subjected to a 10% acrylamide gel containing
sodium dodecyl sulfate and electrotransferred to nitrocellulose
membranes using a Trans-Blot cell system (Bio-Rad). The
membranes were then blocked for at least 2 hr and incubated
overnight with the antibodies against TH or a rabbit policlonal
antibody anti-GAD (Millipore, Temecula, CA, USA). Loading
control with β-actin was conducted in all experiments by using
a mouse monoclonal antibody against β-actin (Sigma, St.
Louis, MO). Optical density obtained from TH and GAD was
ﬁrst normalized in relation to the corresponding β-actin bands
in each experiment. Subsequently, the normalized data were
treated to evaluate protein levels changes in the experimental
side in relation to their controls for each time point.
As described for immunohistochemistry, the TH protein
levels were quantified by the immunoblotting method as an
indication of the lesion extension. GAD levels were investigated
in the striatum and SN to obtain indirect data on GABAergic
neurons. After the quantification blind researchers to the
experimental conditions (side and days after lesion) reviewed
the data.
Statistical Analysis
Quantitative data were submitted to statistical analysis using
GraphPad Prism 5 (San Diego, CA). The comparisons between
control and experimental sides from each group were made
using the Paired Student’s t-test. The comparisons between all
groups were made using the One-Way ANOVA test, followed
by Tukey’s post-test when appropriate. For all tests described,
the significance value adopted was p≤0.05. All data were
normalized to the controls and are expressed as means ±
SEM.
Results
Time course expression of TH, GAD, parvalbumin,
calbindin and CB1 in the basal ganglia of 6-OHDA
injected rats
The analysis of TH, GAD, parvalbumin, calbindin and CB1
protein expression is summarized in Table 1 (immunoblotting)
and in Table 2 (immunohistochemistry), and described in detail
below. Representative digital images are shown in Figures 1-5.
TH expression in the basal ganglia decreases over time
in 6-OHDA injected rats
In general, 6-OHDA produced a decreased TH
immunoreactivity in the injured striatum and SNpc compared to
control side. In the striatum, the 6-OHDA produced a gradual
decrease in the TH immunoreactivity, which was more
pronounced at 10 DPL, followed by a slight increase at 20 and
60 DPL (Table 2, Figure 1A). The mean percentage of TH
expression changes in the immunohistochemistry, as well as
the p values of ANOVA between DPLs over time in the striatum
are shown in Figure 1C. In these later periods, mainly at 60
DPL, we observed TH-positive perikarya in the injured striatum,
when compared to the control side, which normally exhibits TH
immunoreactivity exclusively in the neuropil. These cells were
strongly stained for TH and its frequency was higher in sites
close to the infusion of 6-OHDA (Figure 1B). Semi-quantitative
analysis of the immunoblotting (Table 1) corroborates those
found in immunohistochemistry.
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In the SNpc a gradual and progressive decrease of TH
immunoreactivity was observed in immunohistochemistry
(Table 2, Figure 2A) and in immunoblotting (Table 1). The
mean percentage of TH expression changes in the
immunohistochemistry, as well as the p values of ANOVA
between DPLs over time in the SNpc are shown in Figure 2B.
Time course expression of CB1 changes differentially
in basal ganglia structures of 6-OHDA injected rats
The CB1 analyses were performed only for
immunohistochemistry, because a complex and distinct
structure-related variation of its expression was observed and
the immunoblotting analysis would not allow a detailed spatial
resolution.
Our studies showed that CB1 receptor was present
exclusively in neuropil in all structures of the basal ganglia
analyzed. In the striatum, we found higher densities of CB1 in
its dorsolateral portion. In the GP, CB1 was expressed
throughout the structure, and in the SN, was restricted to the
SNpr. The immunolabelling for CB1 was very specific, as we
had no immunostaining in our negative controls, namely the
omission of primary antibody and preadsorption of the primary
antibody with the corresponding control peptide for CB1 (data
not shown).
In the striatum, our data showed that there is no difference in
the expression of CB1 in injured striatum in all DPL studied
(Table 2 and Figure 6). However, in EGP the time course of
CB1 expression showed a biphasic pattern, with an increase at
short time points, which was gradually decreased at longer
time ones (Table 2 and Figures 3 and 6). As for the EGP, the
time course of CB1 expression in the IGP was biphasic, but
with a different pattern. The increased expression of CB1
occurred only after 1 DPL, followed by a gradual decrease from
5 DPL (Table 2 and Figures 4 and 6). The SNpr exhibited a
gradual decrease in CB1 immunoreactivity that seems to occur
since the shorter time point (Table 2 and Figures 5 and 6).
The CB1 expression data after the lesions are summarized
in Table 3.
(DPL) days post-lesion, (DL) dorsolateral, (EGP) external
globus pallidus, (IGP) internal globus pallidus, (SNpr)
substantia nigra pars reticulata; (
↑↑ ↑ ↑ /↓ ↓ ↓ ↓ very large increase/decrease; (↑↑ ↑ /↓ ↓ ↓ large
increase/decrease; (↑↑ /↓ ↓ moderate increase/decrease; (↑ /↓
little increase/decrease; (=) no change. All in relation to control
side for each group.
The data above were generated by comparisons between
experimental and control sides for each DPL. We have also
performed another statistical comparison (ANOVA) between
the experimental side/control side ratios for each DPL, to
evaluate the differences over time. The mean percentage of
CB1 expression changes in the immunohistochemistry, as well
as the p values of ANOVA between DPLs over time in the
striatum, EGP, IGP, and SNpr are shown in Figure 6.
6-OHDA injection does not change the expression of
GAD and parvalbumin, but increase the calbindin in the
basal ganglia
As CB1 receptors are located in the axon terminals of
GABAergic neurons in the basal ganglia [8], and Walsh et al.
[28] described that the decrease of CB1 expression in SNpr
could be an indirect toxic effect of 6-OHDA to GABAergic
neurons, we have investigated the levels of GAD in the
striatum and SN, and the immunolabeling for parvalbumin and
calbindin in striatum (both immunolabeling known to be co-
localized with GABAergic neurons in basal ganglia [34,35]), to
verify a possible degeneration of these GABAergic neurons in
the striatum caused by 6-OHDA. Semi-quantitative analysis of
immunoblotting data showed no changes in GAD levels in the
striatum and SN for all DPL studied (Table 1 and Figure S1).
Our analysis showed no differences in the number of
parvalbumin positive cells between the control and
experimental striata (Table 2 and Figure S1).
Calbindin was observed mainly in cell body in the
ventromedial portion. There was as an increase about 21% in
the calbindin-positive cells for both 1 and 5 DPL (p<0.01 and
p<0.001, respectively) (Table 2 and Figure S2).
Table 1. Immunoblotting analysis of TH and GAD expression in the basal ganglia of rats after 1, 5, 10, 20, and 60 days of
the 6-OHDA injections (days post-lesion, DPL).
Structure  Protein  
1 DPL CONT
Mean (±SEM)
1 DPL EXP
Mean (±SEM)
5 DPL CONT
Mean (±SEM)
5 DPL EXP
Mean (±SEM)
10 DPL CONT
Mean (±SEM)
10 DPL EXP
Mean (±SEM)
20 DPL CONT
Mean (±SEM)
20 DPL EXP
Mean (±SEM)
60 DPL CONT
Mean (±SEM)
60 DPL EXP
Mean
(±SEM)
Striatum TH 1.00 (±0.08) 0.90 (±0.10) 1.00 (±0.09) 0.72* (±0.08) 1.00 (±0.07) 0.34****(±0.06) 1.00 (±0.07)
0.41****
(±0.06) 1.00 (±0.04)
0.50****
(±0.05)
Striatum GAD 1.00 (±0.18) 1.09 (±0.20) 1.06 (±0.12) 1.02 (±0.17) 1.03 (±0.09) 0.98 (±0.10) 1.06 (±0.09) 1.25 (±0.10) 1.02 (±0.07) 1.00 (±0.14)
SN TH 1.00 (±0.08) 0.99 (±0.06) 1.00 (±0.08) 0.98 (±0.07) 1.00 (±0.07) 0.71**(±0.07) 1.00 (±0.12)
0.54**
(±0.11) 1.00 (±0.07)
0.55***
(±0.03)
SN GAD 1.00 (±0.05) 0.86 (±0.09) 1.00 (±0.14) 1.04 (±0.15) 1.00 (±0.07) 0.96 (±0.08) 1.00 (±0.16) 1.03 (±0.18) 1.03 (±0.13) 1.15 (±0.14)
(DPL) days post-lesion, (CONT) Control side, (EXP) experimental side, (SN) substantia nigra. Statistical analysis by Paired Student’s t test, (*p<0.05; **p<0.01; ***p<0.001,
****p<0.0001 vs control side for each group)
doi: 10.1371/journal.pone.0076874.t001
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Discussion
Our results revealed a complex and distinct structure-specific
variation of CB1 in the basal ganglia over time in 6-OHDA PD
model. This variation was accompanied by an initial general TH
reduction which is reversed by an increase at later periods in
the striatum. No changes in the number of GABAergic neurons
were observed in the striatum.
Several studies have shown the participation of the
cannabinoid system in different neurodegenerative diseases
and suggested its neuroprotective properties [21–23]. In this
context, the high densities of CB1 receptors [1,8] and the
endocannabinoid ligands found in the basal ganglia [15] have
been explored in regard to PD, which has led to prospects for
cannabinoid therapies.
First, to verify a possible relationship between the CB1
expression and the progression of PD, we analyzed the TH
expression as a dopaminergic lesion marker. In general, our
data support the literature data regarding the dopaminergic
neurons death, since we observed a marked decrease of TH
expression in the injured side, both in the striatum and SN. In
the SN this decrease was gradual over the time points studied,
and was more pronounced in the later ones, as described by
several other studies (reviewed by [16,37,38]; [39,40]. On the
other hand, in the striatum we observed a discrete increase in
the TH levels after longer post-lesion periods (20 and 60 DPL),
probably due to the increase of the striatal TH-staining intrinsic
circuitry. Other studies have described a small intrinsic striatal
dopaminergic circuitry [41], that shows a signiﬁcant increase in
the number of TH positive neurons in the dopamine-depleted
striatum [42]
There are few studies establishing a direct relationship
between variation in the CB1 expression and the development
of PD, as well as in animal models of PD. In addition, these
studies, despite generating highly controversial data, are
dedicated in most cases only to the striatum and/or SN
[28,29,43].
First, it is important to note that the immunolabeling for CB1
in the basal ganglia found in our study showed a similar pattern
of localization to other studies conducted with another CB1
antibody in immunohistochemistry [12] or autoradiography [8]
methods. Our data show a decrease in CB1 receptor
expression in the SN, starting at short periods after the 6-
OHDA injection and gradually decreasing over time. In the
striatum, however, no changes in the CB1 expression were
observed, despite the reduction of TH. Interestingly, in the GP
we observed a biphasic time course CB1 variation, with an
initial increase of expression followed by a reduction.
Moreover, this variation was distinct between the external and
internal portions of the GP. In the EGP the increase in the CB1
expression remains until 10 days of the lesion and in the IGP it
was only observed after one day post-lesion. In the case of
earlier time points, we believe that the increased CB1
expression can be related to inflammatory events that occurs in
basal ganglia due to infusion of 6-OHDA. In a mice model of
neuroinflammation with peripheral administration of
lipopolysaccharide (LPS), an increased CB1 mRNA in the
hippocampus and brainstem was seen after 24h [44]. In the PD
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Figure 1.  Temporal changes of TH levels in the striatum of PD-induced rats.  TH levels in striatum of rats submitted to
unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20, and 60 days post-lesion (DPL). (A) Digital images of coronal sections
of the dorsolateral striatum shows a decrease in the expression of TH on the 6-OHDA side, with a peak in 10 DPL (B) Digital images
of coronal sections of the dorsolateral striatum at 60 DPL; the arrow indicates the site of infusion. Note the emergence of TH+ cells
in the experimental side. (C) Semi-quantitative analysis of TH staining represented as percentage. Control side (dashed line).
Statistical analysis by ANOVA (one way) with Tukey post-test. * p <0.05, ** p <0.01 and *** p <0.001.
doi: 10.1371/journal.pone.0076874.g001
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Figure 2.  Temporal changes of TH expression in the SNPc of PD-induced rats.  TH expression in SNpc of rats submitted to
unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20 and 60 days post-lesion (DPL). (A) Digital images of coronal sections of
the SNpc show a progressive decreased TH expression in 6-OHDA side. (B) Semi-quantitative analysis of TH staining represented
as percentage. Control group (dashed line). Statistical analysis by ANOVA (one way) with Tukey post-test. * p <0.05, ** p <0.01 and
*** p <0.001.
doi: 10.1371/journal.pone.0076874.g002
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Figure 3.  Temporal changes of CB1 expression in the EGP of PD-induced rats.  CB1 expression in external globus pallidus
(EGP) of rats submitted to unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20, and 60 days post-lesion (DPL). Digital
images of coronal sections of the EGP show an increase of CB1 expression in the experimental side at earlier time points.
doi: 10.1371/journal.pone.0076874.g003
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Figure 4.  Temporal changes of CB1 expression in the IGP of PD-induced rats.  CB1 expression in internal globus pallidus
(IGP) of rats submitted to unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20 and 60 days post-lesion (DPL). Digital images
of coronal sections of the IGP show an increase in the CB1 expression in the experimental side at 1 DPL. From 5 to 60 DPL, there
was a gradual decrease in the CB1 expression.
doi: 10.1371/journal.pone.0076874.g004
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Figure 5.  Temporal changes of CB1 expression in the SNpr of PD-induced rats.  CB1 expression in the substantia nigra pars
reticulata (SNpr) of rats submitted to unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20 and 60 days post-lesion (DPL).
Digital images of coronal sections of the SNpr show a decrease in the CB1 expression in the experimental side from 5 DPL to 60
DPL.
doi: 10.1371/journal.pone.0076874.g005
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context, it was observed that the CB1 protects nigrostriatal
dopaminergic neurons against MPTP neurotoxicity in mouse,
by preventing microglia-derived oxidative damage, suggesting
a close relationship between the cannabinoid system and
neuroinflammatory events [45]
Decreased levels of CB1 mRNA in the striatum were found in
the PD model induced by reserpine in rats [43] and Walsh et al.
[28] described the reduction of CB1 expression in the SN over
time (1-28 days after lesion) in the 6-OHDA model. Since the
main CB1 location in SNpr is in the GABAergic terminals, the
authors attributed the decrease of CB1 expression to an
indirect toxic effect of 6-OHDA to GABAergic neurons, which
undergo degeneration and consequently decrease the
CB1expression. However, we did not find any differences in
GAD levels in the striatum and SN, neither decrease in the
number of parvalbumin and calbindin positive cells in the
striatum, at any time points studied, which led us to suppose
that the CB1 decrease appears to be unrelated to a possible
Figure 6.  Semi-quantitative analysis of CB1 staining in basal ganglia of PD-induced rats.  The quantification is represented
by percentage in (A) striatum, (B) external globus pallidus (EGP), (C) internal globus pallidus (IGP) and (D) substantia nigra pars
reticulata (SNpr) of rats submitted to unilateral intrastriatal injections of 6-OHDA after 1, 5, 10, 20, and 60 days post-lesion (DPL).
Comparison between the percentage of experimental sides calculated from the control side to each group (dashed line). Statistical
analysis by ANOVA (one way) with Tukey post-test. *p <0.05, **p<0.01 and *** p <0.001.
doi: 10.1371/journal.pone.0076874.g006
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degeneration of GABAergic neurons. Indeed, in the case of
calbindin we observed an increased expression in the striatum
at shorter post-lesion periods, which could be related to its
function as Ca2+ buffering. Studies show that in damaging
processes there is an increase of Ca2+ levels, and the calbindin
may increase the activity to buffering its overload, thus
protecting neurons from excitotoxic damage [46,47].
The decreased levels of CB1 mRNA were also found in post-
mortem brains of PD patients [48]. A recent study employing a
PET technique performed with specific CB1 radioligands
reported a marked CB1 decrease in the SN of PD patients,
concomitant with a slight increase of this receptor in
dopaminergic projection areas [24].
A biphasic pattern of change in CB1 expression in the basal
ganglia was observed in a previous study using mice with
deletion of specific park genes [31,49]. In the early stages of
asymptomatic PD (12 months of age) a desensitization/
downregulation of CB1 occurs in GP and SN, particularly in the
alpha-synuclein-deficient mice, which was associated to a
dopaminergic dysfunction. In contrast, in later stages of PD
(older than 12 months of age), characterized by a deep nigral
degeneration associated to the appearance of parkinsonian
symptoms, was related to a CB1 upregulation [49]. The
expression of CB1 in the GP seems to be influenced by
degenerative processes that affect the basal ganglia, like
Huntington’s disease [50–52], and multiple sclerosis [53].
Although explored in other neurodegenerative diseases, the
CB1 expression in the GP is still not well studied in animal
models of PD. Here we show for the first time the variation in
the CB1 levels in all four basal ganglia structures that express
CB1 in the PD 6-OHDA model, including both GP segments.
This information is essential to understand the involvement of
CB1 in the basal ganglia circuitry in the PD condition.
The literature points to the involvement of cannabinoid
system in the basal ganglia circuitry and that this system is
changed in neurodegenerative diseases [11,49]. It seems that
the endocannabinoid and dopaminergic systems exert a mutual
control on each other. In PD, for example, it has been
suggested that changes in the cannabinoid system may
participate in symptom generation or as part of a compensatory
mechanism to counteract the unbalance in the physiology of
the basal ganglia due to the lack of dopamine [11]. Apart from
the above-mentioned studies on the variations of CB1
expression, other studies showed changes in levels of
endocannabinoids, such as anandamide [54] or changes in
endocannabinoid membrane transporters and fatty acid amide
hydrolase activity [55].
Table 3. Summary of CB1 expression changes in the basal
ganglia.
Structure 1 DPL 5 DPL 10 DPL 20 DPL 60 DPL
Striatum DL = = = = =
EGP ↑↑↑↑ ↑↑ ↑ = ↓
IGP ↑↑↑↑ ↓ ↓↓ ↓↓↓ ↓↓↓
SNpr = ↓ ↓↓ ↓↓↓ ↓↓↓
doi: 10.1371/journal.pone.0076874.t003
In relation to present data, the basal ganglia structure-
specific time course variation in the CB1 expression could be a
plastic response as part of a compensatory mechanism, as
seen in studies of cannabinoid system in other pathways, such
as retinal ablation [36], bilateral vestibular deafferentation [56],
and in pilocarpine-induced epilepsy [57].
The data obtained here on CB1 changes may be related to
GABA-dependent transmission into the basal ganglia. The
decreased GABAergic transmission to SNpr and IGP promotes
an increase in neuronal activity in both structures, whereas the
increase in GABAergic transmission generates a larger
inhibition in EGP [19]. Under physiological conditions, the
activation of pre-synaptic CB1 in GABAergic neurons inhibits
the GABA release [6]. Our hypothesis is that the decrease of
CB1 in SNpr and IGP in the 6-OHDA PD model could be a
plastic response as an attempt to increase the GABAergic
transmission which was altered by the dopaminergic
degeneration. Following the same reasoning, increased CB1
expression in the EGP may lead to a lower release of GABA,
which could recover part of the neuronal activity (Figure 7).
Even for the EGP it is important to remember that despite the
initial CB1 increase in shorter DPL, at 60 DPL there is a
tendency to a decreased expression of CB1. Transient
variations in the CB1 receptor expression has been observed
by our group in different situations in the chick optic tectum,
such as during embryonic development [58] and after retinal
ablation [36]. CB1 receptor variation seems to be common also
in pilocarpine model of epilepsy, which exhibited a
downregulation of hippocampal CB1 receptors in the acute
phase, followed by compensatory upregulation and sprouting in
the chronic phase of lobe temporal epilepsy [59]. Similar
pattern of hippocampal CB1 receptor change was seen in
pilocarpine-induced status epilepticus [57]. These data taken
together suggest the involvement of changes in the CB1
expression in the neurodegenerative processes.
Finally, some authors describe that CB1 may increase local
GABA levels in the EGP by reducing GABA reuptake from
striatal afferents to that nucleus [13,60]. It is then possible that
a decrease of CB1 in EGP at longer DPL is an attempt to
decrease the release of GABA for this structure.
Conclusion
In conclusion, our results indicate a complex modulation of
CB1 expression in the basal ganglia over time after intrastriatal
injections of 6-OHDA, an animal toxin-induced PD model
largely investigated. This modulation is in agreement with data
from transgenic PD animal models and even more important,
data from PD patients. The fact that changes in CB1
expression are structure-specific, led us to speculate that our
data may help to explain the participation of the cannabinoid
system in a possible compensatory mechanism in PD, possibly
related to neuronal plasticity. Furthermore, our data appear to
validate the intrastriatal injection of 6-OHDA as a good PD
model to study the cannabinoid system in PD.
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Supporting Information
Figure S1.  Temporal analysis of GAD levels in basal
ganglia of PD-induced rats. Semi-quantitative analysis from
immunoblotting. Mean ratio of GAD densitometry density data
in relation to beta-actin, comparing the experimental with
control side from each DPL. Statistic analysis by Paired
Student t test.
(TIF)
Figure S2.  Semi-quantitative analysis of calbindin and
parvalbumin staining in basal ganglia of PD-induced rats.
The quantification is represented by percentage in the striatum
of rats submitted to unilateral intrastriatal injections of 6-OHDA
after 1, 5, 10, 20 and 60 days post-lesion (DPL). (A)
Parvalbumin (PV) and (B) Calbidin. Comparison between the
percentage of experimental sides calculated from the control
side to each group (dashed line). Statistical analysis by
ANOVA (one way) with Tukey post-test. *p <0.05, **p<0.01 and
*** p <0.001.
Figure 7.  Scheme of CB1 expression in basal ganglia of PD-induced rats.  Schematic representation of the CB1 receptors
expression in the striatum, external globus pallidus (EGP), internal globus pallidus (IGP) and substantia nigra pars reticulata (SNpr).
This scheme represents control side (A) and intrastriatal 6-OHDA injected side (B). Figure in A depicts the dopaminergic projection
(full gray arrows) of the substantia nigra pars compact (SNpc) to the striatum, and GABAergic projections (full black arrows) of the
striatum to EGP, IGP and SNpr, where CB1 receptors are found (gray squares). Figure in B represents the decreased dopaminergic
(dotted gray arrows) and GABAergic (dotted black arrows) projections, the increased GABAergic projections (thicker full black
arrows), increased CB1expression (bigger gray square), and the decreased CB1 expression (smaller gray square) after 6-OHDA
injection. Our hypothesis is that the decrease of CB1 expression in the direct pathway (SNpr and IGP) could increase the
GABAergic transmission, and the increase of CB1 expression in indirect pathway (EGP) could decrease the GABAergic
transmission, which could together contribute to a restoration of normal thalamic activation. Both events may be a plastic response
of the cannabinoid system due to the lack of dopamine.
doi: 10.1371/journal.pone.0076874.g007
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